

Pediatric Cancer Models and Mechanisms Network

(www.pcommnetwork.ca)

Governance and Scientific Oversight Committee (GSOC): Jason Berman (CHEO), Sonia Cellot (CHUSJ), Jessica Hill (Guelph Wish Fund), Tobias Karakach (Dal), Chris Maxwell (BCCH), Callum Mullen (McGill), Emily Nakada (McGill), Sanja Rogic (UBC, RDMM), Donna Senger (McGill), Anita Villani (SickKids), and Franco Vizeacoumar (University of Saskatchewan)

NEED AND GOAL

The **best outcome for every child with cancer** requires uniform access to the latest molecular and cellular biology knowledge, technologies, and expertise.


The PCMM network **equalizes access across Canada** by creating an “expert registry” and a national matching program for researchers to enable preclinical studies in childhood cancers.

OBJECTIVES

ACCESSIBILITY, TRANSPARENCY, DIVERSITY & COLLABORATION

- The PCMM network is open and accessible to all Canadian researchers for registration and participation.
- The process to join the registry, or to apply for new collaborations, is transparent and accessible through our website;
- Membership in the oversight committee is transparent on our website;
- The **GSOC** includes members with diverse scientific & medical expertise, and career stages (PhD trainee to research institute Director), diverse geography that spans Canada, and diverse life experiences related to childhood cancer;
- All documentation, processes, and procedures are transparent and available at www.pcommnetwork.ca.
- The PCMM network enables collaboration across the pediatric cancer research spectrum, to improve the lives of kids with cancer.**

RESULTS/ IMPACT/ OUTCOMES




ROUND 1 SUMMARY

- July 2024
- 6 applications received from 7 institutions
- 3 prioritized matches identified and funded:
 - Biomarker in Wilms tumor (BCCH)
 - Target in Ewings sarcoma (McGill)
 - Variant function in Leukemia (UBC)
- \$40,000 per collaboration
- Process review (Oct./Nov. 2024) prioritized an increase in per project funding to \$70,000

ROUND 2 SUMMARY

- March 2025
- 7 applications received from 5 institutions
- 4 prioritized matches identified and funded:
 - Pan-cancer patient organoids (Sherbrooke)
 - RMS-organoids (Saskatchewan)
 - Biomarker, CAR-T efficacy (Toronto)
 - Biomarker, ct-DNA (McGill, SickKids)
- \$70,000 per collaboration
- End-of-term report: March 2027

STUDY METHOD



PROJECT TIMELINES

